Profiles of Circulating MiRNAs Following Metformin Treatment in Patients with Type 2 Diabetes
BACKGROUND: Metformin, a widely used biguanide class of anti-diabetic drug, has potential to increase insulin sensitivity and reduce blood glucose to treat type 2 diabetes (T2D). It has been reported that metformin has an activity on regulation of miRNAs by targeting several downstream genes in metabolic pathways. However, molecular mechanism underlying the process is still not fully known. In this study, it was aimed to identify differential expression profiles of plasma derived miRNAs following 3 months metformin treatment in patients with T2D.
METHODS: The plasma samples of 47 patients with T2D (received no anti-diabetic treatments) and plasma samples of same 47 patients received 3 months metformin treatment was recruited to the study. Total RNAs were isolated from plasma and reverse transcribed into cDNA. Profiles of differential expressions of miRNAs in plasma were assessed by using of micro-fluidic based multiplex quantitative real time -PCR (BioMarkTM 96.96 Dynamic Array).
RESULTS: Our results showed that expression profiles of 13 candidate miRNAs; hsa-let-7e-5p, hsa-let-7f-5p, hsa-miR- 21-5p, hsa-miR-24-3p, hsa-miR-26b-5p, hsa-miR-126-5p, hsa-miR-129-5p, hsa-miR-130b-3p, hsa-miR-146a-5p, hsamiR- 148a-3p, hsa-miR-152-3p, hsa-miR-194-5p, hsa-miR- 99a-5p were found significantly downregulated following metformin treatments in patients with T2D (p<0.05).
CONCLUSIONS: In conclusion, our finding could provide development of better and more effective miRNAs based therapeutic strategies against T2D.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Journal of medical biochemistry - 37(2018), 4 vom: 24. Dez., Seite 499-506 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Demirsoy, İbrahim Halil [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 05.10.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2478/jomb-2018-0009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM292137699 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM292137699 | ||
| 003 | DE-627 | ||
| 005 | 20231225072426.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2478/jomb-2018-0009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0973.xml |
| 035 | |a (DE-627)NLM292137699 | ||
| 035 | |a (NLM)30584410 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Demirsoy, İbrahim Halil |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Profiles of Circulating MiRNAs Following Metformin Treatment in Patients with Type 2 Diabetes |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 05.10.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Metformin, a widely used biguanide class of anti-diabetic drug, has potential to increase insulin sensitivity and reduce blood glucose to treat type 2 diabetes (T2D). It has been reported that metformin has an activity on regulation of miRNAs by targeting several downstream genes in metabolic pathways. However, molecular mechanism underlying the process is still not fully known. In this study, it was aimed to identify differential expression profiles of plasma derived miRNAs following 3 months metformin treatment in patients with T2D | ||
| 520 | |a METHODS: The plasma samples of 47 patients with T2D (received no anti-diabetic treatments) and plasma samples of same 47 patients received 3 months metformin treatment was recruited to the study. Total RNAs were isolated from plasma and reverse transcribed into cDNA. Profiles of differential expressions of miRNAs in plasma were assessed by using of micro-fluidic based multiplex quantitative real time -PCR (BioMarkTM 96.96 Dynamic Array) | ||
| 520 | |a RESULTS: Our results showed that expression profiles of 13 candidate miRNAs; hsa-let-7e-5p, hsa-let-7f-5p, hsa-miR- 21-5p, hsa-miR-24-3p, hsa-miR-26b-5p, hsa-miR-126-5p, hsa-miR-129-5p, hsa-miR-130b-3p, hsa-miR-146a-5p, hsamiR- 148a-3p, hsa-miR-152-3p, hsa-miR-194-5p, hsa-miR- 99a-5p were found significantly downregulated following metformin treatments in patients with T2D (p<0.05) | ||
| 520 | |a CONCLUSIONS: In conclusion, our finding could provide development of better and more effective miRNAs based therapeutic strategies against T2D | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a T2D | |
| 650 | 4 | |a metformin | |
| 650 | 4 | |a miRNAs | |
| 650 | 4 | |a qRT-PCR | |
| 700 | 1 | |a Ertural, Duygu Yolal |e verfasserin |4 aut | |
| 700 | 1 | |a Balci, Şenay |e verfasserin |4 aut | |
| 700 | 1 | |a Çınkır, Ümit |e verfasserin |4 aut | |
| 700 | 1 | |a Sezer, Kerem |e verfasserin |4 aut | |
| 700 | 1 | |a Tamer, Lülüfer |e verfasserin |4 aut | |
| 700 | 1 | |a Aras, Nurcan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of medical biochemistry |d 2015 |g 37(2018), 4 vom: 24. Dez., Seite 499-506 |w (DE-627)NLM270452486 |x 1452-8258 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2018 |g number:4 |g day:24 |g month:12 |g pages:499-506 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2478/jomb-2018-0009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2018 |e 4 |b 24 |c 12 |h 499-506 | ||